Objective: To analyze the effects of hemocoagulase agkistrodon (HCA) on the coagulation status of healthy people and traumatic brain injury (TBI) patients in vitro. Methods: A total of 10 TBI patients were enrolled from December 2018 to June 2019,and 24 age and sex matched healthy controls were also enrolled. Clinical and pathological data, blood samples of all subjects were collected. Different gradient concentrations of HCA were added to the blood samples which were detected by thromboelastography, and the R value, K value, α angle and MA value of thromboelastography parameters between the two groups were analyzed to explore the effect of HCA on the coagulation status of patients with TBI. Results: With the increase of HCA concentration in blood samples, the R and K values gradually increased, and the α angles and MA values gradually decreased in both TBI patients group which included 7 males and 3 females, with an median age of 33 (28-39) years old and healthy control group which included 11 males and 13 females, with an median age of 33 (23-49) years old. The differences in the R values, K values, α angles, and MA values of different concentration gradients were statistically significant in both healthy control group and TBI patients group (χ2 were 109.80, 131.28, 185.47, 165.97 and 54.92, 75.60, 80.12, 59.25, respectively, all P<0.001). The differences between R values after adding HCA of 0-0.105 U/ml in the healthy group were statistically significant (P=0.025), but K values, α angles and MA values were not statistically significant (P values were 0.275, 0.206 and 0.330, respectively); the R values of the TBI patients group were not statistically significant after adding HCA of 0 to 0.105 U/ml (P=0.976), and the K values, α angles, and MA values were statistically significant (P values were 0.047, 0.041, and 0.034, respectively).The R values of the healthy control group, the TBI patients group, and the overall data were significantly positively correlated with the HCA dose (r values were 0.552、0.700、0.420, respectively, P<0.001), the K values were significantly positively correlated with the HCA dose (r values were 0.726、0.861、0.750, respectively, P<0.001), the α angles were significantly negatively correlated with the HCA dose (r values were -0.815、-0.876、-0.807, respectively, P<0.001) and the MA values were significantly negatively correlated with the HCA dose (r values were -0.757、-0.710、-0.729, respectively, P<0.001). Conclusions: HCA does not aggravate the procoagulant state of blood in healthy people and TBI patients, and with the increase of HCA concentration in blood, the blood samples of both groups show a tendency to decrease the coagulation ability.
目的： 利用血栓弹力图观察尖吻蝮蛇血凝酶（HCA）在体外对健康人和创伤性脑损伤（TBI）患者凝血状态的影响。 方法： 纳入2018年12月至2019年6月天津医科大学总医院收治的TBI患者10例，同期选择年龄性别匹配的24名健康人作为对照组，收集所有研究对象的临床资料及血液样本。将不同梯度浓度的HCA加入研究血液样本中，进行血栓弹力图检测，分析两组间血栓弹力图参数凝血反应时间（R值）、凝血动力学时间（K值）、凝固角（α角）和最大振幅（MA值），探讨HCA对TBI患者凝血状态的影响。 结果： TBI患者组男7例、女3例，年龄的M（范围）为33（28~39）岁，健康对照组男11例、女13例，年龄的M（范围）为33（23~49）岁。TBI患者组和健康对照组在不同浓度梯度的R值、K值、α角和MA值差异有统计学意义（χ²值分别为109.80、131.28、185.47、165.97和54.92、75.60、80.12、59.25，均P<0.001）。向血液标本中添加HCA浓度越高，TBI患者组和健康对照组R值和K值水平越高，α角和MA值越低。健康对照组在添加0~0.105 U/ml的HCA后R值间的差异有统计学意义（P=0.025），K值、α角和MA值差异均无统计学意义（P=0.275、0.206、0.330）；TBI患者组在添加0~0.105 U/ml的HCA后R值差异无统计学意义（P=0.976），K值、α角和MA值差异均有统计学意义（P=0.047、0.041、0.034）。健康对照组、TBI患者组以及整体数据的R值与HCA添加剂量呈正相关（r=0.552、0.700、0.420，均P<0.001），K值与HCA添加剂量呈正相关（r=0.726、0.861、0.750，均P<0.001），α角与HCA添加剂量均呈负相关（r=-0.815、-0.876、-0.807，均P<0.001），MA值与HCA添加剂量均呈负相关（r=-0.757、-0.710、-0.729，均P<0.001）。 结论： HCA不会加重健康人和TBI患者血液的促凝状态，并且随加入血中HCA浓度增加，两组的血液样本均表现出凝固能力减低的趋势。.